Shares of NovoCure Ltd. (NASDAQ:NVCR) saw unusually-high trading volume on Thursday . Approximately 459,197 shares were traded during trading, an increase of 84% from the previous session’s volume of 249,292 shares.The stock last traded at $7.75 and had previously closed at $7.68.

NVCR has been the subject of several recent analyst reports. Zacks Investment Research downgraded NovoCure from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. JPMorgan Chase & Co. decreased their target price on NovoCure from $29.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, July 29th. Wedbush restated an “outperform” rating and set a $30.00 target price on shares of NovoCure in a research note on Wednesday, July 6th. Deutsche Bank AG decreased their target price on NovoCure from $28.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, July 29th. Finally, Barclays PLC decreased their target price on NovoCure from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Friday, July 29th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. NovoCure currently has an average rating of “Hold” and a consensus price target of $21.43.

The stock’s market capitalization is $664.75 million. The company’s 50-day moving average is $8.89 and its 200-day moving average is $11.68.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, July 28th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.11. The business earned $17.90 million during the quarter, compared to analysts’ expectations of $15.90 million. Equities analysts expect that NovoCure Ltd. will post ($1.74) earnings per share for the current year.

In related news, Director Gert L. Perlhagen sold 676,576 shares of NovoCure stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $1.85, for a total value of $1,251,665.60. Following the sale, the director now owns 676,576 shares of the company’s stock, valued at $1,251,665.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael J. Ambrogi sold 20,000 shares of NovoCure stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total value of $244,800.00. Following the completion of the sale, the chief operating officer now directly owns 324,084 shares in the company, valued at approximately $3,966,788.16. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.